PAUL Y. SONG
M.D., Chief Medical Officer, Cynvenio
A respected clinician and seasoned medical executive with more than two decades of experience in the field of oncology, Dr. Song oversees Cynvenio’s translational and clinical research programs.
Dr. Song is also a member of the faculty at Cedars Sinai Medical Center, in the Samuel Oschin Cancer Center department of radiation oncology and biomedical sciences. In addition, he serves as Chief Medical Officer at AT-Gen Co. Ltd, where he oversees all clinical aspects of the company’s NK Vue, an ELISA-based blood test which measures natural killer cell activity. Previously, Dr. Song served as Chief Medical Officer at Berg Health, where he navigated the company through its launch of several phase I trials. He continues to serve as a Senior Advisor at Berg Health.
Dr. Song graduated with honors from the University of Chicago and received his M.D. degree from George Washington University.
Liquid Biopsy in Immunotherapy and Beyond
We will discuss the latest emerging developments in liquid biopsy technology which provide increased clinical utility particularly in the area of immunotherapy by highlighting several clinical case studies.